Eight Capital Reiterates “Buy” Rating for Hydropothecary (THCX)

Eight Capital reiterated their buy rating on shares of Hydropothecary (CVE:THCX) in a report issued on Thursday morning. Eight Capital currently has a C$3.50 target price on the stock.

Shares of Hydropothecary (CVE:THCX) opened at C$2.52 on Thursday. Hydropothecary has a 1-year low of C$0.68 and a 1-year high of C$3.00.

TRADEMARK VIOLATION WARNING: “Eight Capital Reiterates “Buy” Rating for Hydropothecary (THCX)” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.com-unik.info/2017/12/04/eight-capital-reiterates-buy-rating-for-hydropothecary-thcx.html.

About Hydropothecary

The Hydropothecary Corporation produces and distributes medical marijuana. The company is based in Gatineau, Canada.

What are top analysts saying about Hydropothecary Corp? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Hydropothecary Corp and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit